Luye Pharma Group Ltd.
Comparative Efficacy, Safety, PK, and Immunogenicity Study
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Biological: Denosumab
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 392
- Registration Number
- NCT05853354
- Locations
- 🇯🇵
Gifu Prefectural General Med C., Gifu, Gihu, Japan
🇯🇵Marunouchi Hospital, Matsumoto-shi, Nagano, Japan
🇯🇵Obase Hospital - Orthopedics, Miyako-gun, Hukuoka, Japan
Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05853341
- Locations
- 🇩🇪
SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt, Thüringen, Germany
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Physiological Effects of DrugsPsychotic DisordersTranquilizing AgentsSchizophreniaMood DisordersMental DisordersAntipsychotic AgentsSchizophrenia Spectrum and Other Psychotic DisordersCentral Nervous System DepressionNeurotransmitter Agents
- Interventions
- Drug: LY03010 156 mg treatment group, glutealDrug: LY03010 156 mg treatment group, deltoidDrug: LY03010 351 mg treatment group, deltoidDrug: LY03010 351 mg treatment group, gluteal
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT05321602
- Locations
- 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸CNS Research, Garden Grove, California, United States
🇺🇸NRC Research Institute, Orange, California, United States
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
- Conditions
- Tardive DyskinesiaHuntington Disease
- Interventions
- Drug: LPM3770164 sustained release tabletDrug: LPM3770164 sustained release tablet simulant
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT05238701
- Locations
- 🇨🇳
Shanghai Mental Health Center, Shanghai, Shanghai, China
Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT05140512
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China
Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT05110170
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 448
- Registration Number
- NCT05060406
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
A Study to Evaluate LY06006 and Prolia in Healthy Adults
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 168
- Registration Number
- NCT04973722
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04973735
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
Relative Bioavailability of LY03010 Compared to Listed Drug
- Conditions
- Schizophrenia SpectrumCentral Nervous System DepressantsPhysiological Effects of DrugsPsychotropic DrugsNeurotransmitter AgentsAntipsychotic AgentsTranquilizing AgentsSchizophreniaPsychotic DisordersMood Disorders
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 281
- Registration Number
- NCT04922593
- Locations
- 🇺🇸
Uptown Research Institute, LLC, Chicago, Illinois, United States
🇺🇸Innovative Clinical Research, Inc., Miami Lakes, Florida, United States
🇺🇸Collaborative Neuroscience Network, Inc., Garden Grove, California, United States